Repros enrolls men to test new topical testosterone treatment Androxal

Repros Therapeutics Inc. announced it has completed enrollment for one of two clinical trials pitting its topical testosterone gel alternative Androxal against other topical testosterone products currently on the market. Each trial will include 120 men, who will be divided into groups of 40 for three parallel study arms to test Androxal against an already marketed testosterone gel and a placebo. Studies will run for 17 weeks, which includes 16 weeks of dosing and one week of follow-up to gather information for the conclusion. Repros sought men who were at least 60 years of age who exhibited a normal sperm count ... Read More